Logo
ABBV logo
AbbVie Inc.
ABBV
228.46 (-0.45%) 1.04
Health Care
Biotechnology
AbbVie Inc. a research-based biopharmaceutical company engages in the research and development manufacture commercialization and sale of medicines and therapies worldwide. The company offers Humira an injection for autoimmune and intestinal Behçet's diseases generalized pustular psoriasis and pyoderma gangrenosum; Skyrizi to treat autoimmune diseases erythrodermic psoriasis generalized pustular psoriasis and palmoplantar pustulosis; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta/Venclyxto to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma. It also provides facial injectables plastics and regenerative medicine body contouring and skincare products; botox therapeutic to treat neurologic diseases; Vraylar to treat schizophrenia bipolar disorder and depressive disorder; Duopa and Duodopa to treat Parkinson's disease; Ubrelvy to treat migraine; and Qulipta for episodic and chronic migraine as well as other neuroscience products. In addition the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon a pancreatic enzyme therapy; and Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation. AbbVie Inc. has strategic partnership with OSE Immunotherapeutics. The company was incorporated in 2012 and is headquartered in North Chicago Illinois.

Quality Checklist 1/8

Est. EPS Growth > 5%
5Y Shares Out Change < 0%
ROIC > 10%
Debt/Equity < 1
Current Ratio > 1
Quick Ratio > 1
Net Margin > 10%
Past Net Income CAGR > 0%
0.0%of Portfolio

My holdings

Day change:
Total change:
Shares:
Cost basis:
Market cap: $403.96(B)
EV: $453.09(B)
Total Equity: $-3.23(B)
Earnings date: Apr-24-2026
P/E: 96.40
Forward P/E: 15.73
P/FCF: 22.66
P/S: 6.61
P/B: N/A
EPS: $2.4
EPS (fwd): $14.5
FCF/share: $10.1
Revenue/share: $34.6
Book value/share: $-1.9
ROIC: 3.3%
ROA: 1.7%
ROE: 140.9%
Debt/Equity: 48
Current Ratio: 0.70
Gross margin: 71.6%
Operating margin: 24.1%
Net margin: 6.9%
Dividend/share: $6.7
Div. yield: 2.91%
All Valuation Overview Growth Financials & KPIsCompetitors & Peer Comparison Ownership Tools

Ownership

Major holders

*Excludes indirect insider ownership

Insiders: 0.10%
Institutions: 76.39%
Other: 23.51%

Institutional ownership

10.23% Vanguard Group Inc8.55% Blackrock Inc.4.58% State Street Corporati...2.96% JPMORGAN CHASE & CO2.53% Geode Capital Manageme...2.27% Morgan Stanley1.45% NORGES BANK1.44% Capital Research Globa...1.42% Bank of America Corpor...1.42% Charles Schwab Investm...39.54% Others

Trading Summary

In the past year, insiders have bought $0.00 worth of the company's stock, and sold $68.78(M).

Congress members have bought between $99022 - $485000 worth of the company's stock, and sold between $84021 - $435000.

Insider transactions

$0.002026-03$0.00
$0.002026-02$0.00
$0.002026-01$0.00
$0.002025-12$0.00
$0.002025-11$0.00
$0.002025-10$0.00
$0.002025-09$0.00
$11.05(M)2025-08$0.00
$0.002025-07$0.00
$0.002025-06$0.00
$0.002025-05$0.00
$0.002025-04$0.00
$46.66(M)2025-03$0.00
DateSharesTotal ($)Price ($)NameTitle
Sell2025-08-1242,3708,407,055198.4SALEKI-GERHARDT AZITAChief Operating Officer
Grant2025-08-1242,3702,324,41854.9SALEKI-GERHARDT AZITAChief Operating Officer
Sell2025-08-0513,2952,639,253198.5DONOGHOE NICHOLASOfficer
Grant2025-05-091,20300.0MEYER MELODY BDirector
Grant2025-05-091,20300.0ROBERTS REBECCA B.Director
Grant2025-05-091,20300.0DAVIS JENNIFER LDirector
Grant2025-05-091,20300.0QUAGGIN SUSAN EDirector
Grant2025-05-091,20300.0RAPP EDWARD JDirector
Grant2025-05-091,20300.0ALPERN ROBERT JDirector
Grant2025-05-091,20300.0HART BRETT JDirector
Grant2025-05-091,20300.0BURNSIDE WILLIAM H LDirector
Grant2025-05-091,20300.0FREYMAN THOMAS CDirector
Grant2025-05-091,20300.0FALK THOMAS JDirector
Grant2025-05-091,20300.0AUSTIN ROXANNE SCHUHDirector
Grant2025-05-091,20300.0TILTON GLENN FLETCHERDirector
Grant2025-05-091,20300.0WADDELL FREDERICK HDirector
Sell2025-03-3158,83212,359,504210.1STEWART JEFFREY RYANOfficer
Grant2025-03-3125,7002,030,81479.0STEWART JEFFREY RYANOfficer
Grant2025-03-312,45000.0GONZALEZ RICHARD ADirector
Sell2025-03-1417,6443,746,527212.3REENTS SCOTT T.Chief Financial Officer
Sell2025-03-0327,9005,822,402208.7SIATIS PERRY C.General Counsel
Grant2025-03-0318,0082,879,040159.9SIATIS PERRY C.General Counsel
Sell2025-03-0321,2504,472,039210.4RICHMOND TIMOTHY JOfficer
Sell2025-03-0398,62820,263,020205.4GONZALEZ RICHARD ADirector
Sell2025-02-2618,9443,853,372203.4BUCKBEE KEVIN KOfficer
Grant2025-02-2616,2601,601,31398.5BUCKBEE KEVIN KOfficer
Sell2025-02-2629,9176,070,036202.9RICHMOND TIMOTHY JOfficer
Grant2025-02-2622,2102,539,936114.4RICHMOND TIMOTHY JOfficer
Sell2025-02-205,7781,143,453197.9SIATIS PERRY C.General Counsel

Congressional trading

$0.002026-03$0.00
$0.002026-02$0.00
$0.002026-01$0.00
$0.002025-12$0.00
$80012025-11$0.00
$160012025-10$16001
$0.002025-09$0.00
$240022025-08$24002
$160012025-07$24002
$0.002025-06$16001
$0.002025-05$56502
$1555042025-04$24002
$0.002025-03$16001
DatePoliticianPartyChamberAmount ($)
Sell2025-11-13Julie JohnsonDHouse$1,001 - $15,000
Sell2025-10-31Lisa C. McClainRHouse$1,001 - $15,000
Buy2025-10-30Lisa C. McClainRHouse$1,001 - $15,000
Buy2025-10-30Lisa C. McClainRHouse$1,001 - $15,000
Sell2025-10-30Lisa C. McClainRHouse$1,001 - $15,000
Sell2025-08-22John BoozmanRSenate$1,001 - $15,000
Sell2025-08-14Julie JohnsonDHouse$1,001 - $15,000
Sell2025-08-11John BoozmanRSenate$1,001 - $15,000
Buy2025-08-04Ro KhannaDHouse$1,001 - $15,000
Buy2025-08-04Ro KhannaDHouse$1,001 - $15,000
Buy2025-08-04Marjorie Taylor GreeneRHouse$1,001 - $15,000
Buy2025-07-22Lisa C. McClainRHouse$1,001 - $15,000
Sell2025-07-22Lisa C. McClainRHouse$1,001 - $15,000
Sell2025-07-11Ritchie TorresDHouse$1,001 - $15,000
Buy2025-07-01Ro KhannaDHouse$1,001 - $15,000
Buy2025-07-01Ro KhannaDHouse$1,001 - $15,000
Buy2025-06-17Lisa C. McClainRHouse$1,001 - $15,000
Buy2025-06-17Lisa C. McClainRHouse$1,001 - $15,000
Buy2025-05-28Ro KhannaDHouse$15,001 - $50,000
Buy2025-05-22Josh GottheimerDHouse$1,001 - $15,000
Buy2025-05-15Rob BresnahanRHouse$1,001 - $15,000
Buy2025-05-05Marjorie Taylor GreeneRHouse$1,001 - $15,000
Sell2025-04-17Josh GottheimerDHouse$1,001 - $15,000
Sell2025-04-17Jefferson ShreveRHouse$50,001 - $100,000
Sell2025-04-09Ro KhannaDHouse$15,001 - $50,000
Sell2025-04-08Rob BresnahanRHouse$1,001 - $15,000
Buy2025-04-07Jared MoskowitzDHouse$1,001 - $15,000
Sell2025-04-04Ro KhannaDHouse$1,001 - $15,000
Sell2025-04-04Ro KhannaDHouse$1,001 - $15,000
Sell2025-04-04Ro KhannaDHouse$1,001 - $15,000
Buy2025-04-03Josh GottheimerDHouse$1,001 - $15,000
Sell2025-04-03Dwight EvansDHouse$1,001 - $15,000
Buy2025-04-01Josh GottheimerDHouse$1,001 - $15,000
Buy2025-03-17Marjorie Taylor GreeneRHouse$1,001 - $15,000
Buy2025-03-06Ro KhannaDHouse$1,001 - $15,000
Buy2025-02-25Rob BresnahanRHouse$1,001 - $15,000
Buy2025-02-24Jefferson ShreveRHouse$50,001 - $100,000
Buy2025-02-19Ro KhannaDHouse$15,001 - $50,000
Sell2025-02-05Ro KhannaDHouse$1,001 - $15,000
Sell2025-02-05Ro KhannaDHouse$1,001 - $15,000
Sell2025-02-04Ro KhannaDHouse$1,001 - $15,000
Sell2025-02-04Ro KhannaDHouse$1,001 - $15,000
Sell2025-02-04Ro KhannaDHouse$1,001 - $15,000
(C) PEVALUATOR
About
Terms & privacy
Price charts & news courtesy of TradingView
Blog
Contact